Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study

Summary Background COVID-19 is an ongoing threat to society. Patients who develop the most severe forms of the disease have high mortality. The interleukin-6 inhibitor tocilizumab has the potential to improve outcomes in these patients by preventing the development of cytokine release storm. Aims To...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	QJM : An International Journal of Medicine 2020-08, Vol.113 (8), p.546-550
Hauptverfasser:	Rojas-Marte, G, Khalid, M, Mukhtar, O, Hashmi, A T, Waheed, M A, Ehrlich, S, Aslam, A, Siddiqui, S, Agarwal, C, Malyshev, Y, Henriquez-Felipe, C, Sharma, D, Sharma, S, Chukwuka, N, Rodriguez, D C, Alliu, S, Le, J, Shani, J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - therapeutic use Betacoronavirus Case-Control Studies Coronavirus Infections - drug therapy Coronavirus Infections - mortality COVID-19 COVID-19 Drug Treatment Female Humans Immunosuppressive Agents - therapeutic use Male Middle Aged New York City - epidemiology Original Papers Oxygen Inhalation Therapy Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - mortality Receptors, Interleukin-6 - antagonists & inhibitors SARS-CoV-2 Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!